DexCom, Inc. (DXCM)
DexCom, Inc. (DXCM) is a healthcare company (medical devices) based in the United States. The share price is $82.25, up 0.78% on the day, which values the company at $30.68B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.
Key facts
- Share price
- $82.25+0.78% today
- Market value
- $30.68B
- P/E ratio
- 32.4×last 12 months
- Forward P/E
- 26.2×
- Funk Score
- 83/100
- Against its own history
- Well below its usual priceusual price $199.86
- 200-week average
- $91.1310% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
DexCom, Inc. in more detail
DXCM trades at 32.4× its last twelve months' earnings, 26.2× next year's expected earnings, 6.0× sales. Measured against its own history, the price is 59% below what its usual multiples would imply ($199.86) — well below its usual price. It sits 10% below its 200-week average of $91.13.
Over the last five fiscal years DexCom, Inc. has compounded revenue 19.3% a year, earnings per share 9.5% a year, free cash flow 31.2% a year. Its Funk Score is 83 out of 100 (financial strength 8.3, profitability 8.4, growth 8.7, value 7.7, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score. Worth checking: Gross margin is shrinking.
2 of the superinvestors tracked here hold DXCM, including Baillie Gifford team (1.2% of the portfolio), Jim Simons (1938–2024) (0.3% of the portfolio).
Superinvestors holding DXCM
2 of the investors tracked here report a position in their latest 13F filing.
- Baillie Gifford team Baillie Gifford & Co1.18% of portfolio · $1.3B · trimmed · Q3 2026
- Jim Simons (1938–2024) Renaissance Technologies0.28% of portfolio · $202.5M · added · Q3 2026
Health Care companies of similar size
- AlconALC
- Mettler-Toledo InternationalMTD
- CenteneCNC
- GenmabGMAB
- IlluminaILMN
- ResMedRMD
- ZoetisZTS
- Labcorp HoldingsLH
- Koninklijke PhilipsPHG
- Roivant SciencesROIV
- West Pharmaceutical ServicesWST
- Quest DiagnosticsDGX
Side by side:DXCM vs PHG (DexCom, Inc. vs Koninklijke Philips)DXCM vs LH (DexCom, Inc. vs Labcorp Holdings)DXCM vs ROIV (DexCom, Inc. vs Roivant Sciences)DXCM vs WST (DexCom, Inc. vs West Pharmaceutical Services)DXCM vs DGX (DexCom, Inc. vs Quest Diagnostics)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
DexCom, Inc. (DXCM): questions and answers
What is DXCM's P/E ratio?
DexCom, Inc. trades at 32.4× its last twelve months' earnings and 26.2× next year's expected earnings. At its fiscal year-ends over the past 7 years the P/E ranged from 31.8× to 253.3×, with a median of 95.5×.
What is DXCM's PEG ratio?
DexCom, Inc.'s PEG ratio is 1.31 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is DexCom, Inc.'s market cap?
DexCom, Inc. is valued at $30.68B at a share price of $82.25.
Is DXCM overvalued or undervalued?
Against its own history, DXCM is well below its usual price: the price is 59% below the $199.86 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is DXCM above its 200-week moving average?
No. DXCM is 9.7% below its 200-week average of $91.13. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is DexCom, Inc. growing?
Over the last five fiscal years DexCom, Inc.'s revenue grew 19.3% a year and its earnings per share 9.5% a year; over ten years revenue grew 27.8% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “DexCom, Inc. (DXCM) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/DXCM
Underlying data: Yahoo Finance; company filings with the SEC.